Nature Medicine | Spoonful of Medicine

Analysts weigh in on speculation of further slimming by Pfizer

As economists puzzle over the future direction of global markets, there is a growing consensus among pharmaceutical industry analysts that slimming down will reap profits for Pfizer. Last week the company saw its stock price increase after an analyst at Goldman Sachs wrote that Pfizer’s chief executive, Ian Read, had signaled in a meeting she attended that he may go beyond the divestitures the company has already announced. Pfizer is already in the midst of spinning off its nutritional and animal health businesses, and last week’s news raised speculations from analysts that other divisions may also be destined for the chopping block in the near future. 


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.